Saffron: An Old Medicinal Plant and a Potential Novel Functional Food
María José Bagur, Gonzalo Alonso Salinas, Antonia Jiménez-Monreal et al. · Molecules · 2017 · Review
Full textCC BY
Medicine: papers
Filters2 filters applied
Status
- No notice
- Not checked
- From publisher notices and Retraction Watch. Not checked means nobody has looked yet.
Year
Readable here
Study type
Licence
114 papers37 with full textQuestions on this topic
NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry
Enzo Alessio, Luigi Messori · Molecules · 2019 · Review
Full textCC BY
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
Jake R. Conway, Eric Kofman, Shirley S. Mo et al. · Genome Medicine · 2018 · Review
Full textCC BY
High rates of cancer screening among dialysis patients seen in primary care a cohort study
Bjorg Thorsteinsdottir, LaTonya J. Hickson, Priya Ramar et al. · Preventive Medicine Reports · 2018
Abstract onlyNot checked
Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies
Hongshu Sui, Ningxia Ma, Ying Wang et al. · Journal of Immunology Research · 2018 · Review
Full textCC BY
Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicine
G Smith, R Bounds, H Wolf et al. · British Journal of Cancer · 2010
Full textCC BY
Developing an Integrative Treatment Program for Cancer-Related Fatigue Using Stakeholder Engagement – A Qualitative Study
Claudia Canella MA, Michael Mikolasek MSc, Matthias Rostock MD et al. · Integrative Cancer Therapies · 2018
Abstract onlyNot checked
Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment
Ji Lv, Yitao Jia, Jing Li et al. · Cell Death & Disease · 2019
Full textCC BY
Italian guidelines for the diagnosis and treatment of Paget’s disease of bone
G.C. Isaia, G. Bianchi, S. Gonnelli et al. · Reumatismo · 2011
Abstract onlyNot checked
Future perspectives in melanoma research
Paolo A. Ascierto, Sanjiv Agarwala, Gerardo Botti et al. · Journal of Translational Medicine · 2016
Abstract onlyNot checked
Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response
Elaine R. Mardis · Genome Medicine · 2019
Abstract onlyNot checked
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma
Alexandre Reuben, Christine N. Spencer, Peter A. Prieto et al. · npj Genomic Medicine · 2017
Full textCC BY
Targeting Mortalin by Embelin Causes Activation of Tumor Suppressor p53 and Deactivation of Metastatic Signaling in Human Breast Cancer Cells.
Nupur Nigam, Abhinav Grover, Sukriti Goyal et al. · PLoS ONE · 2015
Abstract onlyNot checked
Validation of serrated polyps (SPs) in Swedish pathology registers
Soran R. Bozorg, Mingyang Song, Louise Emilsson et al. · BMC Gastroenterology · 2019
Abstract onlyNot checked
Clinical development of targeted and immune based anti-cancer therapies
N. A. Seebacher, A. E. Stacy, G. M. Porter et al. · Journal of Experimental & Clinical Cancer Research · 2019 · Review
Full textCC BY
Platinum and ruthenium complexes as promising molecules in cancer therapy
Avramović Nataša, Ignjatović Nikola, Savić Aleksandar · Srpski Arhiv za Celokupno Lekarstvo · 2019
Abstract onlyNot checked
Response to IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor α to gp130 expression: fusing experimental insights and dynamic modelling
Heike Reeh, Nadine Rudolph, Ulrike Billing et al. · Cell Communication and Signaling · 2019
Full textCC BY
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy
Deborah Charych, Samira Khalili, Vidula Dixit et al. · PLOS ONE · 2017
Full textCC BY
Armed and accurate: engineering cytotoxic T cells for eradication of leukemia
Radic Marko · BMC Biotechnology · 2012
Abstract onlyNot checked
Evodiamine synergizes with doxorubicin in the treatment of chemoresistant human breast cancer without inhibiting P-glycoprotein.
Shengpeng Wang, Lu Wang, Zhi Shi et al. · PLoS ONE · 2014
Abstract onlyNot checked